Plus, oh, finding and keeping enough people in the study willing to get 1-3 blood draws a day??? Yow. I thought that by Phase III safety was pretty well estab

Plus, oh, finding and keeping enough people in the study willing to get 1-3 blood draws a day??? Yow. I thought that by Phase III safety was pretty well established and you'd be looking for efficacy endpoints, surrogate or real. Emphasis on endpoint ... but I guess not. But ... if vague memory serves, from the overview of some Phase III trials, maybe not the first one, I remember more like hundreds of participants. Maybe not quite a thousand, but a lot.